Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity

Breast Cancer Research and Treatment

Volumn 113, Issue 1, 2009, Pages 95-100

  Coveler, Andrew L ^a   Goodell, Vivian ^a   Webster, Devon J ^a   Salazar, Lupe G ^a   Fintak, Patricia A ^a   Childs, Jennifer S ^a   Higgins, Doreen M ^a   Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adjuvant; Aromatase inhibitors; Bisphosphonates; HER 2 neu; Immunity; Lymphocyte; T cell; Tamoxifen; Trastuzumab; Vaccine

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CANCER VACCINE; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MECHANISM; HORMONAL THERAPY; HUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; BREAST NEOPLASMS; CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; T-LYMPHOCYTES;

EID: 58049221253     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-9910-y     Document Type: Article

References (27)

1. OJ Finn 2003 Cancer vaccines: between the idea and the reality Nat Rev Immunol 3 8 630 641
2. ML Disis FM Shiota MA Cheever 1998 Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens Immunology 93 2 192 199
3. RS Day SE Shackney WP Peters 2005 The analysis of relapse-free survival curves: implications for evaluating intensive systemic adjuvant treatment regimens for breast cancer Br J Cancer 92 1 47 54
4. A Nicolini A Carpi G Rossi 2006 Cytokines in breast cancer Cytokine Growth Factor Rev 17 5 325 337
5. ML Disis TA Gooley K Rinn 2002 Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines J Clin Oncol 20 11 2624 2632
6. DJ Webster J Waisman B Macleod 2006 A phase I/II study of a HER2/neu (HER2) peptide vaccine plus concurrent trastuzumab J Clin Oncol 24 18S 2528
7. LG Salazar AL Coveler RE Swensen 2007 Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers Clin Immunol 125 3 275 280
8. ML Disis KH Grabstein PR Sleath 1999 Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine Clin Cancer Res 5 6 1289 1297
9. ML Disis KL Knutson K Schiffman 2000 Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer Breast Cancer Res Treat 62 3 245 252
10. AL Sommer BK Wachel JA Smith 2006 Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy J Oncol Pharm Pract 12 3 143 154
11. PP Sfikakis GM Gourgoulis LA Moulopoulos 2005 Age-related thymic activity in adults following chemotherapy-induced lymphopenia Eur J Clin Invest 35 6 380 387
12. VA Morrison KR Rai BL Peterson 2001 Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: intergroup Study Cancer and Leukemia Group B 9011 J Clin Oncol 19 16 3611 3621
13. H Zhou P Zou ZC Chen 2007 A novel vicious cycle cascade in tumor chemotherapy Med Hypotheses 69 6 1230 1233
14. MX Sliwkowski JA Lofgren GD Lewis 1999 Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Semin Oncol 26 4 Suppl 12 60 70
15. M Marty F Cognetti D Maraninchi 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 19 4265 4274
16. AM Wolf H Rumpold H Tilg 2006 The effect of zoledronic acid on the function and differentiation of myeloid cells Haematologica 91 9 1165 1171
17. A Bringmann SM Schmidt MM Weck 2007 Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells Leukemia 21 4 732 738
18. V Paharkova-Vatchkova R Maldonado S Kovats 2004 Estrogen preferentially promotes the differentiation of CD11c+ CD11b(intermediate) dendritic cells from bone marrow precursors J Immunol 172 3 1426 1436
19. G Nalbandian V Paharkova-Vatchkova A Mao 2005 The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation J Immunol 175 4 2666 2675
20. VG Premkumar S Yuvaraj K Vijayasarathy 2007 Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin Basic Clin Pharmacol Toxicol 100 6 387 391
21. D Sereda VP Werth 2006 Improvement in dermatomyositis rash associated with the use of antiestrogen medication Arch Dermatol 142 1 70 72
22. M Dayan H Zinger F Kalush 1997 The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations Immunology 90 1 101 108
23. E Yang XF Hu PX Xing 2007 Advances of MUC1 as a target for breast cancer immunotherapy Histol Histopathol 22 8 905 922
24. RA Clynes TL Towers LG Presta 2000 Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat Med 6 4 443 446
25. L Arnould M Gelly F Penault-Llorca 2006 Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94 2 259 267
26. DP Braun KA Crist F Shaheen 2005 Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity Am J Surg 190 4 570 571
27. J Berry BJ Green DS Matheson 1987 Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminoglutethimide Cancer Immunol Immunother 24 1 72 75